InnoCare Pharma (9969) Q2 2025 earnings summary

Executive summary

• Achieved two landmark drug approvals in China: Orelabrutinib for first-line CLL/SLL and CD19 antibody Minjuvi/Tafasitamab for R/R DLBCL, opening new commercialization opportunities.

• Revenue for H1 2025 rose 74.3% year-over-year to RMB 731.4 million, driven by strong orelabrutinib sales and licensing revenue from Prolium.

• Net loss narrowed by 86.7% to RMB 35.6 million, reflecting improved operational efficiency and sales growth.

• Maintained a strong cash position of RMB 7.7 billion as of June 30, 2025, supporting R&D and business expansion.

• Strategic global partnerships, notably with Prolium, and robust R&D progress underpin long-term growth.

Financial highlights

• Total revenue for H1 2025 reached RMB 731.4 million, up 74.3% year-over-year, with drug sales of RMB 641 million, up 53.5%.

• Gross profit increased 82.1% to RMB 654.7 million, with gross margin rising to 89.5%.

• Net loss for the period narrowed by 86.7% to RMB 35.6 million; adjusted loss was RMB 15.5 million.

• R&D expenses for H1 2025 were RMB 450 million, up 6.9% year-over-year.

• Cash and related balances stood at RMB 7.7 billion as of June 30, 2025.

Outlook and guidance

• Confident in exceeding 35% annual growth guidance for Orelabrutinib, with strong momentum from new indications.

• NDA for Zurletrectinib accepted and under priority review, with approval expected in H1 2026.

• Multiple registrational trials ongoing or planned for Orelabrutinib and Mesutoclax in hematology and autoimmune indications.

• Focus on accelerating global expansion through partnerships and advancing key pipeline assets.

• R&D expenses expected to grow 15%-20% annually over the next two years to support global trials and platform expansion.